Findings of transoesophageal echocardiogram in appropriately anticoagulated patients with persistent atrial fibrillation prior to planned cardioversion

被引:13
作者
Barysiene, Jurate [1 ,2 ]
Zebrauskaite, Aiste [1 ,2 ]
Petrikonyte, Dovile [1 ,2 ]
Marinskis, Germanas [1 ,2 ]
Aidietiene, Sigita [1 ,2 ]
Aidietis, Audrius [1 ,2 ]
机构
[1] Vilnius Univ Hosp, Santariskiu Clin, Ctr Cardiol & Angiol, 2 Santariskiu St, LT-08661 Vilnius, Lithuania
[2] Vilnius Univ, Clin Cardiovasc Dis, Fac Med, 21 Ciurlionio St, LT-03101 Vilnius, Lithuania
来源
BMC CARDIOVASCULAR DISORDERS | 2017年 / 17卷
关键词
Atrial fibrillation; Non-vitamin K antagonist oral anticoagulants; Anticoagulation; Cardioversion; Transoesophageal echocardiogram; Thromboembolism; ORAL ANTICOAGULANTS; THERAPY; RISK; DABIGATRAN; MANAGEMENT; EFFICACY; THROMBUS; EVENTS; GUIDE;
D O I
10.1186/s12872-017-0503-8
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: To evaluate a diagnostic value of transoesophageal echocardiogram (TEE) in appropriately anticoagulated patients with a non-valvular atrial fibrillation (AF) and to establish possible additional indications for TEE; to evaluate the incidence of left atrial (LA) thrombi in appropriately anticoagulated patients in daily clinical practice. Methods: This retrospective study analyses data of 432 patients who had been anticoagulated by means of oral anticoagulants (OACs) prior to planned cardioversion during the period from 2012 to 2015. Thromboembolic (TE) and bleeding risks were assessed using CHA2DS2-VASc and HAS-BLED scores. Transthoracic and transoesophageal echocardiograms were evaluated. TE complications during 30 days after discharge were assessed. Results: 432 patients were selected, aged from 22 to 89 years (mean 65.0 +/- 11.5), 277 (64.1%) males and 155 (35.9%) females, 306 (70.8%) on warfarin and 126 (29.2%) on non-vitamin K antagonist oral anticoagulants (NOAC). Mean CHA2DS2-VASc score was 3.5 +/- 1.5. TEE was performed for 120 (27.8%) patients, more frequently for patients on NOACs and for ones with III degrees LA enlargement. TEE revealed LA thrombi in seven (5.8%) of the patients. In warfarin and NOACs groups thrombi were revealed in five (7.0%) and two (4.1%) patients, respectively. TEE did not reveal any thrombi in patients with normal left ventricular (LV) function; however, thrombi were found in two (6.1%) patients with slightly decreased LV function, and in five (17.9%) patients with markedly decreased LV function. In patients with decreased left ventricular ejection fraction (LVEF) thrombi in LA were found more frequently than in patients with normal and slightly decreased LVEF (17.9% vs 2.2%, p=0.008). CHA2DS2-VASc score of all 7 patients was >= 5. None of the patients after cardioversion had TE complications 30 days after discharge. Conclusions: The risk of LA thrombi in patients prepared for scheduled cardioversion in line with the guidelines is low. Higher risk of thrombi was present in patients with decreased LVEF (<= 40%), CHA2DS2-VASc >= 5. In order to assess more accurately indications to perform TEE for appropriately anticoagulated patients prior to scheduled cardioversion a study with larger number of patients is required.
引用
收藏
页数:8
相关论文
共 22 条
  • [1] Effect of Weight Reduction and Cardiometabolic Risk Factor Management on Symptom Burden and Severity in Patients With Atrial Fibrillation A Randomized Clinical Trial
    Abed, Hany S.
    Wittert, Gary A.
    Leong, Darryl P.
    Shirazi, Masoumeh G.
    Bahrami, Bobak
    Middeldorp, Melissa E.
    Lorimer, Michelle F.
    Lau, Dennis H.
    Antic, Nicholas A.
    Brooks, Anthony G.
    Abhayaratna, Walter P.
    Kalman, Jonathan M.
    Sanders, Prashanthan
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2013, 310 (19): : 2050 - 2060
  • [2] ROLE OF PROPHYLACTIC ANTICOAGULATION FOR DIRECT-CURRENT CARDIOVERSION IN PATIENTS WITH ATRIAL-FIBRILLATION OR ATRIAL-FLUTTER
    ARNOLD, AZ
    MICK, MJ
    MAZUREK, RP
    LOOP, FD
    TROHMAN, RG
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1992, 19 (04) : 851 - 855
  • [3] EFFICACY OF ANTICOAGULANT THERAPY IN PREVENTING EMBOLISM RELATED TO DC ELECTRICAL CONVERSION OF ATRIAL FIBRILLATION
    BJERKELUND, CJ
    ORNING, OM
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 1969, 23 (02) : 208 - +
  • [4] . Optimal Anticoagulation Strategy for Cardioversion in Atrial Fibrillation
    Bushoven, Philipp
    Linzbach, Sven
    Vamos, Mate
    Hohnloser, Stefan H.
    [J]. ARRHYTHMIA & ELECTROPHYSIOLOGY REVIEW, 2015, 4 (01) : 44 - 46
  • [5] CARDIOVERSION OF NONRHEUMATIC ATRIAL-FIBRILLATION - REDUCED THROMBOEMBOLIC COMPLICATIONS WITH 4 WEEKS OF PRECARDIOVERSION ANTICOAGULATION ARE RELATED TO ATRIAL THROMBUS RESOLUTION
    COLLINS, LJ
    SILVERMAN, DI
    DOUGLAS, PS
    MANNING, WJ
    [J]. CIRCULATION, 1995, 92 (02) : 160 - 163
  • [6] Ejection fraction and risk of thromboembolic events in patients with systolic dysfunction and sinus rhythm: Evidence for gender differences in the studies of left ventricular dysfunction trials
    Dries, DL
    Rosenberg, YD
    Waclawiw, MA
    Domanski, MJ
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1997, 29 (05) : 1074 - 1080
  • [7] Efficacy and Safety of Apixaban in Patients After Cardioversion for Atrial Fibrillation
    Flaker, Greg
    Lopes, Renato D.
    Al-Khatib, Sana M.
    Hermosillo, Antonio G.
    Hohnloser, Stefan H.
    Tinga, Brian
    Zhu, Jun
    Mohan, Puneet
    Garcia, David
    Bartunek, Jozef
    Vinereanu, Dragos
    Husted, Steen
    Harjola, Veli Pekka
    Rosenqvist, Marten
    Alexander, John H.
    Granger, Christopher B.
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2014, 63 (11) : 1082 - 1087
  • [8] Left atrial thrombus and prognosis after anticoagulation therapy in patients with atrial fibrillation
    Fukuda, Shota
    Watanabe, Hiroyuki
    Shimada, Kenei
    Aikawa, Masaru
    Kono, Yasushi
    Jissho, Satoshi
    Taguchi, Haruyuki
    Umemura, Jun
    Yoshiyama, Minoru
    Shiota, Takahiro
    Sumiyoshi, Tetsuya
    Yoshikawa, Junichi
    [J]. JOURNAL OF CARDIOLOGY, 2011, 58 (03) : 266 - 277
  • [9] Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation
    Heidbuchel, Hein
    Verhamme, Peter
    Alings, Marco
    Antz, Matthias
    Diener, Hans-Christoph
    Hacke, Werner
    Oldgren, Jonas
    Sinnaeve, Peter
    Camm, A. John
    Kirchhof, Paulus
    [J]. EUROPACE, 2015, 17 (10): : 1467 - 1507
  • [10] Is one month treatment with dabigatran before cardioversion of atrial fibrillation sufficient to prevent thromboembolism?
    Johansson, Anna-Karin
    Juhlin, Tord
    Engdahl, Johan
    Lind, Stefan
    Hagwall, Kristina
    Rorsman, Cecilia
    Fodor, Emoke
    Alenholt, Anna
    Nordin, Astrid Paul
    Rosenqvist, Marten
    Frick, Mats
    [J]. EUROPACE, 2015, 17 (10): : 1514 - 1517